LOGIN  |  REGISTER
Cue Biopharma

List of Medical Device Stocks

Company
Last Trade
Change
Volume
Shares Out
Market Cap
US$ 113.12
-0.36 -0.32
1.19M
1.74B
US$ 196.830B
US$ 398.98
-1.12 -0.28
208,475
354.45M
US$ 141.420B
US$ 357.50
-1.21 -0.34
152,207
380.26M
US$ 135.940B
US$ 87.04
0.12 0.14
1.45M
1.33B
US$ 115.760B
US$ 68.60
-0.03 -0.04
749,701
1.47B
US$ 100.830B
US$ 247.42
0.89 0.36
156,498
288.90M
US$ 71.480B
US$ 95.05
-0.10 -0.11
1.30M
601.30M
US$ 57.150B
US$ 83.09
-0.19 -0.23
188,618
493.24M
US$ 40.980B
US$ 397.49
3.39 0.86
34,816
73.21M
US$ 29.100B
US$ 197.69
1.35 0.69
126,511
147.09M
US$ 29.080B
US$ 132.55
-0.06 -0.05
439,106
205.08M
US$ 27.180B
US$ 327.66
-0.25 -0.08
66,905
75.10M
US$ 24.610B
US$ 225.11
-0.41 -0.18
45,732
98.81M
US$ 22.240B
US$ 42.78
0.09 0.21
435,425
507.83M
US$ 21.720B
US$ 101.88
0.03 0.03
194,289
198.76M
US$ 20.250B
US$ 77.54
0.19 0.25
300,816
234.73M
US$ 18.200B
US$ 94.00
0.14 0.15
62,390
137.67M
US$ 12.940B
US$ 328.35
5.74 1.78
274,096
37.40M
US$ 12.280B
US$ 169.95
0.77 0.46
215,718
69.93M
US$ 11.880B
US$ 25.60
-0.74 -2.81
1.35M
437.16M
US$ 11.190B
US$ 224.32
0.45 0.20
41,870
47.06M
US$ 10.560B
US$ 186.63
1.88 1.02
72,176
55.77M
US$ 10.410B
US$ 227.11
0.73 0.32
101,615
38.70M
US$ 8.790B
US$ 346.09
-3.47 -0.99
22,916
23.42M
US$ 8.110B
US$ 146.04
1.56 1.08
236,901
52.91M
US$ 7.730B
US$ 33.12
-0.19 -0.57
749,577
207.36M
US$ 6.870B
US$ 219.84
6.34 2.97
136,009
30.30M
US$ 6.660B
US$ 17.32
0.11 0.64
26,163
350.99M
US$ 6.080B
US$ 53.67
0.61 1.15
117,434
112.94M
US$ 6.060B
US$ 93.28
0.59 0.64
64,748
49.47M
US$ 4.610B
US$ 75.94
0.48 0.64
24,439
57.93M
US$ 4.400B
US$ 84.14
0.05 0.06
72,021
50.79M
US$ 4.270B
US$ 117.65
2.59 2.25
43,467
33.40M
US$ 3.930B
US$ 21.45
-0.11 -0.51
226,320
171.55M
US$ 3.680B
US$ 116.07
0.31 0.27
55,377
30.98M
US$ 3.600B
US$ 69.00
0.10 0.15
182,227
51.00M
US$ 3.520B
US$ 60.98
1.55 2.61
65,537
55.77M
US$ 3.400B
US$ 56.43
0.55 0.98
50,203
53.96M
US$ 3.040B
US$ 48.36
0.96 2.03
399,177
57.96M
US$ 2.800B
US$ 34.63
-0.20 -0.57
92,169
78.22M
US$ 2.710B
US$ 49.88
1.04 2.13
105,518
50.96M
US$ 2.540B
US$ 104.97
2.08 2.02
25,991
24.14M
US$ 2.530B
US$ 76.89
2.77 3.74
322,912
32.72M
US$ 2.520B
US$ 80.96
0.82 1.02
59,134
30.78M
US$ 2.490B
US$ 35.45
0.15 0.42
231,080
65.63M
US$ 2.330B
US$ 13.93
0.13 0.94
429,144
137.98M
US$ 1.920B
US$ 51.96
1.29 2.55
38,246
36.99M
US$ 1.920B
US$ 37.93
0.23 0.61
52,619
48.87M
US$ 1.850B
US$ 21.61
0.41 1.93
220,168
84.26M
US$ 1.820B
US$ 15.43
0.79 5.40
894,939
107.09M
US$ 1.650B
US$ 11.46
0.10 0.88
164,384
132.91M
US$ 1.520B
US$ 67.31
0.11 0.16
8,283
22.34M
US$ 1.500B
US$ 30.11
-0.03 -0.10
52,446
47.59M
US$ 1.430B
US$ 51.28
0.52 1.02
89,184
27.20M
US$ 1.390B
US$ 13.61
0.36 2.72
305,316
98.37M
US$ 1.340B
US$ 7.65
0.04 0.53
235,043
146.96M
US$ 1.120B
US$ 31.65
-0.22 -0.69
71,766
34.87M
US$ 1.100B
US$ 12.25
0.34 2.85
245,666
82.84M
US$ 1.010B
US$ 20.00
0.10 0.50
22,611
46.20M
US$ 924.000M
US$ 21.75
0.12 0.55
36,813
41.23M
US$ 896.750M
US$ 23.43
0.50 2.18
89,228
38.06M
US$ 891.750M
US$ 6.64
0.01 0.15
136,855
130.82M
US$ 868.640M
US$ 18.76
0.29 1.57
67,052
45.30M
US$ 849.600M
US$ 12.94
0.58 4.69
50,295
61.76M
US$ 799.170M
US$ 453.86
5.86 1.31
16,844
1.76M
US$ 798.790M
US$ 18.06
0.43 2.44
102,174
40.62M
US$ 733.600M
US$ 18.69
-0.02 -0.11
72,887
39.17M
US$ 732.090M
US$ 29.71
0.74 2.55
26,123
23.55M
US$ 699.670M
US$ 1.19
-0.01 -0.83
1.02M
586.80M
US$ 698.290M
US$ 16.75
0.93 5.88
143,722
41.06M
US$ 687.760M
US$ 3.83
0.33 9.43
132,553
156.55M
US$ 599.590M
US$ 10.04
0.16 1.62
880,710
57.73M
US$ 579.610M
US$ 43.40
0.03 0.07
5,292
12.66M
US$ 549.440M
US$ 14.57
0.28 1.96
50,810
37.41M
US$ 545.220M
US$ 14.44
0.02 0.14
86,246
36.40M
US$ 525.620M
US$ 8.79
0.39 4.64
26,084
55.08M
US$ 484.150M
US$ 6.22
0.08 1.30
99,380
73.80M
US$ 459.220M
US$ 16.59
0.28 1.72
53,880
27.08M
US$ 449.300M
US$ 4.30
-0.03 -0.58
203,037
104.13M
US$ 447.240M
US$ 16.32
-0.18 -1.09
38,358
25.71M
US$ 419.590M
US$ 12.62
0.04 0.32
16,249
32.17M
US$ 405.820M
US$ 16.19
0.33 2.08
29,101
23.60M
US$ 382.080M
US$ 18.21
0.22 1.22
42,595
20.93M
US$ 381.140M
US$ 13.43
-0.20 -1.47
3,739
28.34M
US$ 380.610M
US$ 13.26
0.00 0.00
8,078
28.68M
US$ 380.300M
US$ 9.68
0.30 3.20
25,825
38.76M
US$ 375.120M
US$ 9.39
0.28 3.07
39,307
38.54M
US$ 361.890M
US$ 7.93
0.16 2.06
18,661
43.21M
US$ 342.660M
US$ 5.29
0.12 2.33
16,744
63.38M
US$ 334.960M
US$ 37.25
-0.05 -0.13
702
8.54M
US$ 318.120M
US$ 0.56
-0.0086 -1.53
1.14M
530.67M
US$ 294.520M
US$ 5.32
0.14 2.70
33,572
49.55M
US$ 263.610M
US$ 7.11
0.01 0.14
3,890
36.93M
US$ 262.390M
US$ 9.79
0.35 3.71
7,892
26.41M
US$ 258.420M
US$ 70.18
0.00 0.00
2,640
3.63M
US$ 254.750M
US$ 2.49
0.06 2.26
197,073
99.17M
US$ 246.440M
US$ 7.13
0.18 2.59
48,620
32.91M
US$ 234.650M
US$ 5.84
0.14 2.46
86,278
39.86M
US$ 232.780M
US$ 4.67
-0.06 -1.27
25,064
49.14M
US$ 229.480M
US$ 2.65
0.14 5.58
82,798
82.13M
US$ 217.640M
US$ 29.71
1.16 4.06
13,699
7.03M
US$ 208.850M
US$ 8.30
0.02 0.24
3,920
24.43M
US$ 202.770M
US$ 1.06
-0.005 -0.47
168,942
181.71M
US$ 191.700M
US$ 8.08
0.12 1.51
31,802
23.33M
US$ 188.510M
US$ 4.41
0.07 1.61
20,557
42.10M
US$ 185.660M
US$ 8.72
-0.08 -0.91
13,512
21.20M
US$ 184.860M
US$ 4.25
0.05 1.19
14,461
43.40M
US$ 184.450M
US$ 1.17
0.06 5.41
82,024
130.11M
US$ 152.240M
US$ 16.68
0.27 1.65
1,749
8.61M
US$ 143.610M
US$ 21.79
0.00 0.00
0
6.33M
US$ 137.930M
US$ 5.60
-0.01 -0.18
20,766
24.49M
US$ 137.140M
US$ 2.33
0.13 5.91
85,496
50.51M
US$ 117.690M
US$ 4.86
-0.23 -4.44
173,291
22.92M
US$ 111.490M
US$ 2.42
0.14 6.15
52,301
45.71M
US$ 110.390M
US$ 1.91
0.06 2.99
61,563
54.98M
US$ 104.760M
US$ 3.47
-0.03 -0.85
20,413
28.49M
US$ 98.860M
US$ 5.37
0.12 2.29
47,325
16.64M
US$ 89.270M
US$ 1.79
0.03 1.70
1,324
47.69M
US$ 85.370M
US$ 4.06
0.15 3.84
19,714
19.55M
US$ 79.370M
US$ 2.47
0.16 7.05
21,384
31.63M
US$ 78.220M
US$ 5.36
0.08 1.52
13,808
13.32M
US$ 71.400M
US$ 3.24
0.09 2.86
520
19.96M
US$ 64.670M
US$ 3.92
-0.005 -0.13
13,380
16.39M
US$ 64.170M
US$ 1.77
0.03 1.72
33,806
36.04M
US$ 63.790M
US$ 0.23
-0.0015 -0.64
567,784
271.99M
US$ 63.240M
US$ 17.66
0.25 1.44
793
3.51M
US$ 61.990M
US$ 3.50
0.00 0.00
0
17.64M
US$ 61.740M
US$ 1.93
-0.02 -1.03
73,393
30.99M
US$ 59.810M
US$ 1.02
0.02 2.00
8,397
56.84M
US$ 57.980M
US$ 2.41
0.12 5.41
19,602
23.46M
US$ 56.420M
C$ 0.86
0.00 0.00
0
65.03M
C$ 55.930M
US$ 1.19
0.00 0.00
28,450
45.73M
US$ 54.420M
US$ 2.57
0.00 0.00
0
20.76M
US$ 53.350M
US$ 3.06
0.11 3.56
23,597
16.25M
US$ 49.640M
US$ 0.91
-0.02 -2.14
15,545
54.29M
US$ 49.400M
US$ 0.31
0.02 5.99
141,816
156.13M
US$ 48.370M
US$ 0.63
0.0009 0.14
51,110
76.19M
US$ 48.030M
US$ 1.36
-0.05 -3.55
27,069
34.64M
US$ 47.110M
US$ 0.97
-0.02 -1.92
166,108
48.00M
US$ 46.610M
C$ 0.41
0.00 0.00
1,200
101.40M
C$ 41.570M
US$ 3.61
-0.15 -4.09
10,322
11.40M
US$ 41.110M
US$ 0.52
0.0034 0.66
33,699
73.93M
US$ 38.460M
US$ 4.29
0.01 0.23
2,637
8.96M
US$ 38.440M
C$ 0.32
0.00 0.00
0
118.47M
C$ 37.910M
C$ 0.17
0.00 0.00
161,121
228.46M
C$ 37.700M
US$ 0.98
-0.0099 -1.00
31,620
37.19M
US$ 36.450M
US$ 6.06
0.19 3.24
3,600
6.00M
US$ 36.360M
US$ 1.21
0.02 1.66
12,144
29.94M
US$ 36.220M
US$ 2.19
0.07 3.30
461,654
16.29M
US$ 35.670M
C$ 0.23
0.00 0.00
28,000
156.82M
C$ 35.280M
US$ 1.60
0.13 8.50
241,955
21.65M
US$ 34.530M
US$ 1.19
-0.02 -1.66
51,865
25.93M
US$ 30.730M
US$ 1.46
0.07 5.04
520,511
19.96M
US$ 29.140M
US$ 0.07
-0.0003 -0.42
5,844
389.89M
US$ 27.570M
US$ 1.39
-0.03 -2.11
39,152
17.90M
US$ 24.880M
US$ 2.33
0.06 2.42
1,240
10.54M
US$ 24.510M
US$ 1.75
-0.01 -0.57
49,675
14.00M
US$ 24.500M
US$ 0.02
-0.0006 -2.78
620,000
1.14B
US$ 23.940M
C$ 0.45
0.02 4.65
17,450
52.67M
C$ 23.700M
C$ 0.12
0.005 4.35
11,000
194.28M
C$ 23.310M
C$ 0.34
-0.005 -1.47
3,000
69.23M
C$ 23.190M
US$ 0.40
-0.71 -63.87
26,889
55.68M
US$ 22.410M
US$ 2.40
-0.33 -12.09
65,142
8.05M
US$ 19.320M
US$ 0.76
-0.02 -2.31
13,987
25.08M
US$ 19.110M
US$ 1.05
-0.02 -1.87
15,378
16.77M
US$ 17.610M
US$ 1.17
0.02 1.62
26,717
14.40M
US$ 16.830M
US$ 8.97
0.09 1.01
2,808
1.82M
US$ 16.330M
US$ 0.95
0.06 6.74
40,292
16.82M
US$ 15.980M
US$ 2.65
-0.02 -0.75
1,450
5.74M
US$ 15.210M
US$ 0.39
-0.05 -12.23
86,877
35.05M
US$ 13.690M
US$ 0.45
-0.005 -1.11
6,395
29.98M
US$ 13.340M
C$ 0.07
0.00 0.00
43,000
188.08M
C$ 13.170M
US$ 4.54
0.09 1.91
15,400
2.84M
US$ 12.880M
US$ 1.37
0.01 0.74
6,040
9.26M
US$ 12.690M
US$ 2.74
-0.04 -1.44
13,503
4.06M
US$ 11.120M
US$ 0.60
-0.01 -2.04
2,151
17.39M
US$ 10.500M
US$ 0.12
0.00 0.00
637
73.90M
US$ 8.870M
US$ 0.75
0.00 0.00
0
11.77M
US$ 8.830M
US$ 4.28
0.12 2.84
2,185
1.99M
US$ 8.510M
US$ 1.33
0.00 0.00
0
6.19M
US$ 8.230M
US$ 0.12
0.0005 0.43
267,858
65.56M
US$ 7.710M
US$ 1.02
0.24 30.13
1.75M
7.29M
US$ 7.400M
US$ 0.10
-0.13 -54.74
3,792
66.78M
US$ 6.960M
US$ 0.70
-0.03 -4.11
134,894
9.33M
US$ 6.530M
US$ 4.55
-0.10 -2.23
25,353
1.33M
US$ 6.050M
US$ 0.19
-0.008 -4.04
57,806
29.30M
US$ 5.570M
US$ 0.34
-0.0099 -2.86
14,030
15.27M
US$ 5.130M
US$ 5.75
0.15 2.68
1,750
886,743
US$ 5.100M
US$ 2.93
-0.01 -0.34
2,186
1.70M
US$ 4.980M
C$ 0.02
0.005 33.33
2,000
246.29M
C$ 4.930M
US$ 1.71
0.00 0.00
527
2.62M
US$ 4.480M
US$ 0.70
-0.02 -2.67
7,024
6.36M
US$ 4.460M
US$ 0.18
0.0023 1.27
651,226
23.46M
US$ 4.300M
US$ 0.20
0.0049 2.56
3.21M
19.20M
US$ 3.760M
US$ 0.50
0.01 2.04
4,597
7.03M
US$ 3.520M
US$ 0.04
0.006 18.18
38,500
83.12M
US$ 3.240M
US$ 1.13
0.03 2.32
6,810
2.49M
US$ 2.800M
US$ 0.38
-0.01 -3.48
173,184
6.80M
US$ 2.580M
US$ 0.08
-0.02 -20.23
1,259
28.90M
US$ 2.430M
US$ 0.93
0.03 3.31
26,930
2.60M
US$ 2.420M
US$ 0.75
0.05 6.66
5,127
3.14M
US$ 2.360M
US$ 0.45
0.00 0.00
0
4.88M
US$ 2.180M
US$ 2.18
0.14 6.86
10,143
879,176
US$ 1.920M
US$ 0.90
-0.04 -3.97
20,023
2.05M
US$ 1.830M
US$ 1.20
0.01 0.84
3,446
1.47M
US$ 1.760M
US$ 0.80
-0.0085 -1.06
1,689
1.78M
US$ 1.420M
US$ 0.08
-0.02 -20.80
750
9.74M
US$ 772K
US$ 0.0008
0.0001 14.29
10,000
463.12M
US$ 370K
US$ 5.19
0.00 0.00
7,303
-
US$ -
US$ 0.30
0.00 0.00
191
-
US$ -
C$ 1.30
0.00 0.00
200
-
C$ -

Latest News From Medical Device Stocks


ReShape Lifesciences® Receives Notice of Allowance for Additional U.S. Patent Related to an Intragastric Balloon System

IRVINE, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- ReShape Lifesciences® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced that the company has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for patent application 18/370,819, entitled, “Intragastric Device.” When issued, the patent will cover claims for an intragastric balloon system, comprising a capsule configured to be... Read more


NanoVibronix Signs Agreement for Research and Development of Next Generation PainShield and UroShield

Efforts Focused on Adding Therapeutic Functionality and Reducing Costs ELMSFORD, N.Y. / Mar 28, 2024 / Business Wire / NanoVibronix, Inc. (Nasdaq: NAOV) (“NanoVibronix” or the “Company”), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced it has entered into an agreement with Veranex, Inc. (“Veranex”) to assist with the development of the... Read more


Nexalin Technology Announces Positive Results of Clinical Study Validating its Gen-2 tACS Device for Reducing Pain Among Veterans with Mild Traumatic Brain Injury at University of California, San Dieg

Collaborative Study involving the VA and UCSD achieved statistically significant decrease in PCS and PTSD symptoms versus control group The data supports the Company’s strategy to offer military and civilian physicians a new tool to effectively treat mTBI without the use of medication, and without side effects or adverse events HOUSTON, TEXAS, March 28, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) today... Read more


Biomerica InFoods IBS Data to be Presented at the Upcoming Digestive Disease Week (DDW) 2024 Conference

Collaborators at the University of Michigan will present new Data on InFoods® IBS in the DDW Irritable Bowel Syndrome (IBS) Clinical Session IRVINE, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ: BMRA), a global biomedical company at the forefront of innovative gastroenterology solutions, proudly announces that data from collaborators at the University of Michigan utilizing its groundbreaking inFoods IBS technologies will be presented in the IBS... Read more


BrainsWay Announces Positive Results in Late-Life Depression Post-Marketing Analysis

JERUSALEM and BURLINGTON, Mass., March 28, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, announced positive results in a recently published post-marketing study of its Deep Transcranial Magnetic Stimulation (Deep TMS™) for the treatment of late-life depression. The data were highlighted in an article entitled, “Never... Read more


Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Year 2023 Financial Results

SEATTLE, March 28, 2024 (GLOBE NEWSWIRE) -- Perspective, Therapeutics, Inc. (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today provided a business update and announced fiscal year 2023 financial results for the period ended December 31, 2023.  “We made tremendous progress during 2023 in building a fully integrated radiopharmaceuticals company dedicated to advancing potentially... Read more


Tenon Medical Appoints Kristine Jacques to its Board of Directors

Experienced Medical Devices Industry Executive Joins Tenon's Board of Directors LOS GATOS, CA / ACCESSWIRE / March 28, 2024 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company transforming care for patients suffering with certain sacroiliac joint disorders, today announced that Kristine Jacques has been appointed as an independent member of the Company's Board of Directors on March 25, 2024, effective immediately. Following this appointment, Tenon... Read more


QHSLab Announces Impressive 2023 Fiscal Year Results with Growing Revenues, Improved Gross Margins, and Substantial Reduction in Net Loss

WEST PALM BEACH, FL, March 28, 2024 (GLOBE NEWSWIRE) -- QHSLab, Inc. (the “Company”) (OTCQB: USAQ), a company focused on providing clinicians with tools to leverage proactive, value-based healthcare solutions through emerging digital health and point-of-care technologies, today reported its financial and operational results for the fiscal year ended December 31, 2023. The year was marked by robust revenue growth, significant improvements in gross margins, and a strategic... Read more


NeuroPace to Present at the Needham 23rd Annual Healthcare Conference

MOUNTAIN VIEW, Calif., March 27, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it will present at the Needham 23rd Annual Healthcare Conference, taking place virtually from April 8-11. Joel Becker, NeuroPace’s Chief Executive Officer, will provide a corporate presentation on Monday, April 8 at 3:45pm ET, and management will participate in one-on-one meetings... Read more


Hamilton Thorne Reports Record Revenue and EBITDA for the Quarter and Year Ended December 31, 2023

BEVERLY, Mass. and TORONTO, March 27, 2024 (GLOBE NEWSWIRE) -- Hamilton Thorne Ltd. (TSX: HTL), a leading provider of precision instruments, laboratory equipment, consumables, software and services to the Assisted Reproductive Technologies (ART), research, and cell biology markets, today reported audited financial results for the fourth quarter and year-ended December 31, 2023. Financial Highlights Sales for the year increased 16% to $67.2 million; sales for the quarter... Read more


Medtronic announces FDA approval of newest-generation Evolut TAVR system for treatment of symptomatic severe aortic stenosis

The Evolut™ FX+ TAVR system leverages market-leading valve performance with addition of larger windows to facilitate coronary access DUBLIN, March 27, 2024 /CNW/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that the United States Food and Drug Administration (FDA) has approved the Evolut™ FX+ transcatheter aortic valve replacement (TAVR) system for the treatment of symptomatic severe aortic stenosis. The latest Evolut... Read more


MiMedx Provides Update on AXIOFILL® Request for Designation (“RFD”) from FDA

Receives Determination Letter from FDA Stating AXIOFILL Does Not Qualify for Classification as an HCT/P Under Section 361 MIMEDX Continues to Pursue All Available Options to Keep AXIOFILL on the Market Reiterates Expectations for 2024 Net Sales Percentage Growth in the Low Double Digits and 2024 Adjusted EBITDA1 Margin Above 20% MARIETTA, Ga., March 27, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced... Read more


Novocure: METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell...

The METIS trial demonstrated 21.9 months median time to intracranial progression for patients treated with Tumor Treating Fields and supportive care compared to 11.3 months for patients treated with supportive care alone Novocure to host investor conference call at 8 a.m. EDT ROOT, Switzerland / Mar 27, 2024 / Business Wire / Novocure (NASDAQ: NVCR) today announced the phase 3 METIS clinical trial met its primary endpoint, demonstrating a statistically significant... Read more


Bausch + Lomb Will Present New Scientific Data and Analyses at the American Society of Cataract and Refractive Surgery Annual Meeting

Presentations Will Feature Studies Evaluating TENEO™ Excimer Laser Platform, MIEBO® (Perfluorohexyloctane Ophthalmic Solution) and enVista® Envy* and IC-8® Apthera™ IOLs VAUGHAN, Ontario / Mar 27, 2024 / Business Wire / Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced fifteen podium and four poster presentations during the American Society of Cataract and Refractive... Read more


EDAP TMS Reports Fourth Quarter and Full-Year 2023 Financial Results

Record Q4 2023 total revenue of EUR 19.6 million ($21.3 million USD) increased 24.8% over Q4 2022 Record Q4 2023 HIFU revenue of EUR 7.5 million ($8.1 million USD), an increase of 38.8% over Q4 2022 Record full-year 2023 total revenue of EUR 60.4 million ($65.4 million USD) increased 9.6% over full-year 2022 Record full-year 2023 HIFU revenue of EUR 20.6 million ($22.3 million USD), an increase of 31.7% over full-year 2022 Strong Q4 2023 U.S. Focal One® HIFU procedure... Read more


Theralase Technologies Release's 4Q2023 Interim Financial Statements

TORONTO, ON / ACCESSWIRE / March 27, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light and/or radiation activated Photo Dynamic Compounds ("PDCs") for the safe and effective destruction of various cancers, bacteria and viruses has released the Company's audited annual consolidated 2023 financial statements ("Financial Statements"). Theralase®... Read more


Spectral AI Announces 2023 Fourth Quarter and Full Year Financial Results

2023 Research & Development Revenue of $18.1 Million Expected to Increase to $28.0 Million in 2024 Commercialization Underway with Revenue Expected in 2H 2024 for DeepView AI®-Burn Indication in the UK On Track for Additional Regulatory Submissions in US and UK for DeepView™ System Burn and Diabetic Foot Ulcer Indications DALLAS, March 27, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial... Read more


STRATA Skin Sciences Reports Fourth Quarter and Full-Year 2023 Earnings

HORSHAM, Pa., March 27, 2024 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN) (“STRATA” or “the Company”), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, today announced financial results for the fourth quarter and full-year ended December 31, 2023. Fourth Quarter and Full-Year 2023 and Recent Business Highlights: Revenue in the fourth quarter... Read more


PAVmed Provides Business Update and Fourth Quarter and Full Year 2023 Financial Results

Lucid's quarterly revenue increased 33 percent sequentially Launched wholly-owned incubator, PMX, to complete development and commercialization of existing portfolio technologies Conference call and webcast to be held tomorrow, March 27th at 8:30 AM ET NEW YORK, March 26, 2024 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics,... Read more


LeMaitre Vascular to Present at the 23rd Annual Needham Virtual Healthcare Conference

BURLINGTON, Mass., March 26, 2024 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that JJ Pellegrino, Chief Financial Officer, will present virtually at the 23rd Annual Needham Virtual Healthcare Conference on Wednesday, April 10, 2024, at 11:30 AM ET. About LeMaitre LeMaitre is a provider of devices, implants and services for the treatment of peripheral vascular disease, a condition that affects more than 200 million people worldwide. The Company... Read more


Stevanato Announces Closing of Upsized Public Offering of Ordinary Shares and Exercise in Full of the Underwriters’ Option to Purchase Additional Ordinary Shares

PIOMBINO DESE, Italy / Mar 26, 2024 / Business Wire / Stevanato Group S.p.A. (NYSE: STVN) (“Stevanato Group,” or the “Company”), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, today announced the closing of its previously announced upsized underwritten public offering of an aggregate of 14,605,000 of its ordinary shares, which includes the full exercise of the... Read more


Sight Sciences to Present at the Upcoming 23rd Annual Needham Healthcare Conference

MENLO PARK, Calif., March 26, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today announced it will present at the upcoming 23rd Annual Needham Healthcare Conference being held virtually. Sight Sciences’ management is scheduled to present on Tuesday,... Read more


NeuroOne Medical Technologies Initiates Limited Commercial Launch of OneRF™ Ablation System

First to market FDA-cleared thin-film, sEEG-guided RF system capable of both recording electrical activity and ablating nervous tissue with the added benefit of temperature control Limited commercial launch initiated earlier than expected EDEN PRAIRIE, Minn., March 26, 2024 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company focused on improving surgical care options and... Read more


HeartSciences Announces Podium Presentation at World Congress of Anesthesiologists on the Utility of MyoVista® Wavelet ECG For Detection of Left Ventricular Diastolic Dysfunction in Preoperative Pati

Southlake, Texas, March 26, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced the podium presentation of a study utilizing its MyoVista® wavECG device at the 18th World Congress of Anesthesiologists in Sing... Read more


Intelligent Bio Solutions to Present at the LD Micro Invitational XIV Investor Conference on April 9 in NYC

NEW YORK, March 26, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. ("INBS" or the "Company") (Nasdaq: INBS), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that President and CEO, Harry Simeonidis, and CFO, Spiro Sakiris, are scheduled to present at the LD Micro Invitational XIV Investor Conference to be held on April 8-9, 2024 in New York City. LD Micro Invitational XIV Investment ConferenceDates:... Read more


TriSalus Life Sciences Technology Featured in Two Presentations at the Society of Interventional Radiology Annual Scientific Meeting

New safety and feasibility data from Phase 1/1b PERIO-03 trial for locally advanced pancreatic cancer supports further development of the novel TriSalus Infusion System for therapeutic delivery via retrograde venous delivery  A retrospective clinical study of the Pressure-Enabled Drug Delivery™ (PEDD™) method supports selection of the TriNav® Infusion System for treatment-refractory hypovascular tumors  DENVER & SALT LAKE CITY / Mar 26, 2024 / Business... Read more


Tenon Medical Announces Positive Fusion Results in First Patients Reaching 12-Month Follow Up in an IRB Approved, Multi-Centered, Post-Market Study Utilizing the Catamaran(R) SI Joint Fusion System

Preliminary SI Joint Fusion Results Based on Independent Radiologist Review Indicate Robust Fusion at 12-Months Post-Procedure Initial Patient Results Demonstrate Marked Improvements in Pain Scores and Disability, Along with High Patient Satisfaction Ratings LOS GATOS, CA / ACCESSWIRE / March 26, 2024 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company transforming care for patients suffering with certain sacroiliac joint disorders, today announced... Read more


Accuray: New Data from Two Clinical Studies Indicate High-Risk and Recurrent Prostate Cancers Can be Effectively Treated in 5 Days Using the Accuray CyberKnife® System

Data Also Underscores Potential Benefits of CyberKnife System Sub-millimeter Accuracy in Preserving Quality of Life after Treatment for Prostate Cancer MADISON, Wis., March 26, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that new data presented at the 2024 Radiosurgery Society Meeting in Chicago, Illinois support the use of the CyberKnife® System in the treatment of high-risk and recurrent prostate cancer. The studies expand on years... Read more


InspireMD Announces Abstract of One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial Accepted for Presentation at LINC 2024

TEL AVIV, Israel and MIAMI, March 26, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced that an abstract of the one-year outcomes from its C-GUARDIANS IDE clinical trial of the CGuard™ Prime Carotid Stent System for the treatment of carotid artery stenosis has been accepted for presentation at the Leipzig Interventional Course (LINC) 2024, which is being... Read more


Modular Medical Announces Steve Gemmell as New Vice President of Engineering

SAN DIEGO, CA / ACCESSWIRE / March 26, 2024 / Modular Medical, Inc. (NASDAQ:MODD) ("Modular Medical" or the "Company"), a development-stage, insulin delivery technology company seeking to launch the next generation of user-friendly and affordable insulin pump technology, today announced the addition of Steve Gemmell as Vice President of Engineering. Gemmell has over 20 years of experience in medical device product development and operations and previously held R&D... Read more


Delcath Systems Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update

Increases 2024 Treatment Site Activation Guidance to 20 Sites QUEENSBURY, N.Y., March 26, 2024 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH) ("Delcath" or the "Company"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported recent business highlights and financial results for the fourth quarter and full year ended December 31, 2023. Recent Business Highlights During and since the fourth... Read more


Vivani Medical Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

Strategic shift prioritizes the development of GLP-1 implants for the treatment of obesity and chronic weight management Positive NPM-115 (exenatide implant) preclinical weight loss data comparable to semaglutide, active ingredient in Ozempic®/Wegovy® $15 million financing round enables acceleration of priority development programs and secures operations into the second half of 2025 ALAMEDA, Calif. / Mar 26, 2024 / Business Wire / Vivani Medical, Inc. (Nasdaq: VANI)... Read more


Iridex Reports Fourth Quarter and Full Year 2023 Financial Results

MOUNTAIN VIEW, Calif., March 26, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today reported financial results for the fourth quarter and full year ended December 30, 2023, and provided a business update. Fourth Quarter 2023 Results & Recent Highlights Generated total revenue... Read more


ProSomnus Reports Record Fourth Quarter and Fiscal Year 2023 Financial Results

PLEASANTON, Calif., March 26, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA), the leading non-CPAP therapy™ for the treatment of Obstructive Sleep Apnea (OSA), today announced financial results for the fourth quarter and year ended December 31, 2023. Recent Business Highlights Generated record revenues of $7.8 million for the fourth quarter and $27.7 million for the fiscal year 2023, a 35% increase compared to $5.8 million for the fourth quarter 2022 and... Read more


Sanara MedTech Announces Fourth Quarter and Full Year 2023 Results

FORT WORTH, TX, March 25, 2024 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (NASDAQ: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets, announced today its strategic, operational and financial... Read more


Inspira™ Technologies Reports Full Year 2023 Financial Results

FDA Submission for approval of INSPIRA™ ART100 95% Accuracy Results for HYLA™ Blood Sensor Compared to Standard Blood Gas Analyzers Granted U.S. Patent for INSPIRA™ ART Medical Device RA'ANANA, Israel, March 25, 2024 /PRNewswire/ -- Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) (the "Company" or "Inspira Technologies"), a breakthrough medical technology company, today announced its financial results for the year ended December... Read more


Inogen To Present at 23rd Annual Needham Virtual Healthcare Conference

GOLETA, Calif. / Mar 25, 2024 / Business Wire / Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced management will participate in the 23rd Annual Needham Virtual Healthcare Conference. Kevin Smith, President and Chief Executive Officer, and Michael Bourque, Chief Financial Officer, are scheduled to participate in a fireside chat on Tuesday, April 9, 2024, at 9:30 a.m. Eastern... Read more


Nyxoah Advances Patient Access Strategy through Partnership with the American Association of Otolaryngology – Head & Neck Surgery Foundation

First medical device company to become a corporate champion at the ENTerprise Circle level Mont-Saint-Guibert, Belgium – March 25, 2024, 7:05am CET / 2:05am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company has signed a strategic partnership to become a Corporate... Read more


Lucid Diagnostics Provides Business Update and Preliminary Fourth Quarter and Full Year 2023 Financial Results

Quarterly EsoGuard® revenue increased 33 percent sequentially Expanding EsoGuard clinical validity and clinical utility data poised to drive medical policy coverage, including line of sight to Medicare coverage Conference call and webcast to be held tomorrow, March 26th at 8:30 AM ET NEW YORK, March 25, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company,... Read more


Tivic Health Systems Reports Fiscal Year 2023 Financial Results

SAN FRANCISCO / Mar 25, 2024 / Business Wire / Tivic Health® Systems, Inc. (“Tivic”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced its financial results for the year ending December 31, 2023. Tivic’s commercial platform is a handheld design that interfaces non-invasively with the trigeminal, sympathetic, and other facial and cranial nerve structures. This platform is the basis for Tivic’s existing product,... Read more


Sanuwave Health Announces Record Q4 and FY2023 Revenue

Q4 2023 revenues were a record $7.0 million, up 27% from Q4 2022 FY 2023 revenues were a record $20.4 million, up 22% from FY2022 Operating income was $1 million for Q4 2023 compared to an operating loss of $1.5 million for Q4 2022 Company provides guidance for revenue growth of 45-55% for Q1 2024 vs Q1 2023 and initiates annual guidance for FY2024 of 50% revenue growth vs. FY2023 EDEN PRAIRIE, MN, March 22, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire - SANUWAVE... Read more


TELA Bio Achieves Record Fourth Quarter and Full Year 2023 Revenues and Reports Complete Financial Results

MALVERN, Pa., March 21, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy, today reported financial results for the fourth quarter and full year ended December 31, 2023. Recent Highlights Reported revenue of $17.0 million in the fourth quarter... Read more


Lucid Diagnostics Announces Positive Data from the First Prospective Clinical Validation Study of EsoGuard® Esophageal Precancer Testing in a Screening Population

Prospective VA screening study demonstrates excellent EsoGuard sensitivity of 92.9% and negative predictive value of 98.6% compared to upper gastrointestinal endoscopy Authors conclude that EsoGuard is a "powerful screening tool" for esophageal precancer and cancer NEW YORK, March 21, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned... Read more


PAVmed Launches Incubator to Advance Existing Pipeline Technologies including PortIO, EsoCure and CarpX

The incubator, PMX, and medical device firm Hatch Medical, execute joint venture agreement to complete their development and commercialization, starting with PortIO NEW YORK, March 21, 2024 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that it has launched a wholly owned incubator, PMX,... Read more


Allurion Technologies Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 Guidance

NATICK, Mass. / Mar 21, 2024 / Business Wire / Allurion Technologies, Inc. (NYSE: ALUR) (“Allurion”), a company dedicated to ending obesity, today reported financial results for the fourth quarter and full year ended December 31, 2023, and reiterated 2024 guidance. Fourth Quarter Highlights and Outlook Reiterating 2024 guidance on procedural volume, revenue, gross margin, and cash burn Fourth quarter revenue of $8.2 million and full year 2023 revenue of $53.5 million,... Read more


TriSalus Life Sciences Announces Oral Presentations at the Upcoming 2024 Society of Interventional Radiology (SIR) Annual Scientific Meeting

DENVER / Mar 21, 2024 / Business Wire / TriSalus Life Sciences® Inc. (Nasdaq: TLSI), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, announced today that the Company will present data from recent research findings at the 2024 Society of Interventional Radiology (SIR) Annual Scientific Meeting, to be held March 23-28, 2024, in Salt Lake City, Utah. TriSalus will share data... Read more


Apyx Medical Reports Fourth Quarter and Full Year 2023 Financial Results; Introduces Full Year 2024 Financial Outlook

Advanced Energy Sales increased 15% year-over-year and 23% quarter-over-quarter in the fourth quarter; increased 18% year-over-year in 2023 CLEARWATER, Fla. / Mar 21, 2024 / Business Wire / Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical;” the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today reported financial results for its fourth quarter and full year ended December 31, 2023,... Read more


TELA Bio Announces U.S. Commercial Launch of LIQUIFIX™ – the Only FDA-Approved Liquid Adhesive for Internal Use in Hernia Surgery

MALVERN, Pa., March 21, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced the U.S. launch of LIQUIFIX FIX8™ Laparoscopic and LIQUIFIX Precision™ Open Hernia Mesh Fixation Devices. LIQUIFIX FIX8 is indicated for minimally invasive femoral and inguinal hernia repairs; and LIQUIFIX Precision is indicated for open femoral and inguinal... Read more


Asensus Surgical Reports Operating and Financial Results for the Fourth Quarter 2023 and Full Year 2023

RESEARCH TRIANGLE PARK, N.C., March 21, 2024 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient, announced its operating and financial results for the fourth quarter and full year 2023. Full Year Highlights Completed in vivo evaluation of the LUNA™ Surgical System by nine independent surgeons through thirteen procedures across gynecology, urology, and general... Read more


Hyperfine Reports Fourth Quarter and Full Year 2023 Financial Results

GUILFORD, Conn., March 21, 2024 (GLOBE NEWSWIRE) -- Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced fourth quarter and full year 2023 financial results and provided a business update. “I am pleased with our strong growth in 2023. We continued to drive adoption in our beachhead markets of... Read more

COPYRIGHT ©2023 HEALTH STOCKS HUB